HOPKINTON, Mass. and FREMONT, Calif., Oct. 7 — Caliper Life Sciences, Inc. (Nasdaq: CALP) and DiscoveRx, today announced the commercial availability of PathHunter(TM) eXpress Beta-Arrestin kits for use with Caliper’s LabChip(R) 3000 and EZ Reader(TM) platforms to conduct cellular G protein-coupled receptor (GPCR) assays. This milestone is part of the collaboration between Caliper and DiscoveRx, announced in May 2008, to provide a powerful and comprehensive suite of solutions to assist pharmaceutical and biotechnology researchers in more efficiently discovering new drugs.

“This joint solution enables researchers to quickly assess potency and potential side effects of new drug candidates in a cellular environment, which accelerates overall drug discovery programs,” said Nate Cosper, Director of Marketing at Caliper Life Sciences. “Achievement of this commercial milestone underscores Caliper’s commitment to partnering with leading technology companies like DiscoveRx to develop innovative solutions that provide higher quality and more reproducible data, improve scientific workflows and enable novel research approaches.”

Caliper’s LabChip 3000 and EZ Reader platforms, a suite of instruments for screening and profiling potential drug candidates, utilize microfluidic separation and direct detection of both substrates and products to generate high quality, reproducible data to qualify potential lead candidates. Caliper provides researchers in neuroscience, cardiovascular, and inflammation therapeutic areas with platforms and services for target validation, receptor screening, side effect profiling, functional cellular assays, in vivo efficacy studies using IVIS technology, and in vivo pharmacodynamic analysis.

“PathHunter eXpress Beta-Arrestin kits for use with Caliper’s LabChip instruments contain everything needed to perform screening or profiling experiments: cells, detection reagents, media and plates. The workflow improvements inherent to this complete solution for live-cell GPCR experiments enables scientists to spend more of their time designing better and safer drugs,” said Sailaja Kuchibhatla, Senior Vice President of Business Development at DiscoveRx. “Today’s announcement further signifies the momentum generated by our partnership with Caliper and the relationships they are helping us develop with customers in secondary screening and profiling laboratories.”